Delhi-based pregnancy and fertility platform Crysta, which is operated by Redcliffe Life Sciences, has raised Rs 10 crore in a seed round led by family office of the Jaipuria Group, according to a statement issued by the company.
Other investors in the round include Green Shots Capital, Alfa Ventures, Real Time Ventures, NGB Dx, Dubai-based Petrotech, Steel City Securities as well as angel investors Lalit Washwa and Kriti Maroli.
Founded in 2018 by Dheeraj Jain and Ashish Dubey, Redcliffe Life Sciences offers DNA-based diagnostic services, and has diversified interests in rare disorders, oncology and clinical gene sequencing. It has partnered with hospitals and laboratories for genomic testing of samples.
Redcliffe’s Crysta platform offers diagnostic and screening services as well as counselling and clinical data management for mother and child health. The range of tests include pre-conception and fertility tests, non-invasive prenatal screening and pre-implantation genetic screening for IVF centres.
“The pre-series A funding will help us in building an end-to-end reproductive health platform covering all relevant aspects of pregnancy and fertility care. The potential is huge in this segment, and the current round will allow us to scale up Crysta and our other capabilities across major cities,” Jain, Redcliffe’s founder said in a statement. “We are also preparing for the $10 million Series A round for a much-larger expansion in the mother and child segment.”
Niche healthcare and health technology companies have spiked the interest of early and growth stage investors. In December, multi-speciality clinic chain for elective surgeries Pristyn Care raised $12 million in Series B round from Hummingbird Ventures and Greenoaks Capital. In November, dermatology-focused healthcare platform BeYouPlus raised $3.2 million in a Series A round led by IvyCap Ventures. Wound-care product maker Axio Biosolution raised $5.2 million led by Omidyar Network earlier this month.